샘플 요청 목록

 카트 문의
시장보고서
상품코드
2034244

급성 폐손상 치료 시장 : 시장 인사이트, 경쟁 구도 및 시장 예측(2033년)

Acute Lung Injury Treatment Market Insights, Competitive Landscape, and Market Forecast - 2033
발행일: | 리서치사: 구분자 Fairfield Market Research | 페이지 정보: 영문 192 Pages | 배송안내 : 2-5일 (영업일 기준)

    
    
    



가격
Unprintable PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.
US $ 4,995 금액 안내 화살표 ￦ 7,602,000
Unprintable PDF & Excel (Multi User License upto 5 users) help
PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.
US $ 8,495 금액 안내 화살표 ￦ 12,930,000
Printable PDF & Excel (Enterprise License above 5 users) help
PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,600 금액 안내 화살표 ￦ 16,134,000
카드담기
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 각국의 의료 시스템이 중증 호흡기질환에 대한 대응을 강화하는 가운데, 급성 폐손상 치료 시장은 꾸준히 발전하고 있습니다. 급성 호흡곤란 증후군(ARDS)을 포함한 급성폐손상(ALI)은 복잡한 병태생리와 높은 치사율로 인해 여전히 심각한 문제로 남아있습니다. 호흡기 감염, 패혈증, 외상 및 환경적 위험 요소의 발생률이 증가함에 따라 효과적인 치료 개입의 필요성이 더욱 커지고 있습니다. 의료진은 생존율과 환자 예후를 개선하기 위해 조기 진단과 고급 치료 전략에 점점 더 집중하고 있습니다. 집중 치료 의학의 끊임없는 발전과 호흡기 건강에 대한 인식이 높아지면서 선진국과 개발도상국을 막론하고 이 시장의 확대에 기여하고 있습니다.

시장 인사이트

급성 폐 손상 치료 시장 규모는 2026년 31억 달러에서 2033년까지 39억 달러로 확대될 것으로 예상되며, 예측 기간 동안 3.30%의 CAGR을 기록할 것으로 예상됩니다. 이러한 성장은 집중 치료 및 호흡기 보조 요법에 대한 수요 증가에 힘입은 것입니다. 약물 치료는 인공호흡기 관리 및 산소 요법과 함께 여전히 치료 프로토콜의 주요 구성요소입니다. 또한, 중증 환자의 체외막형 인공호흡기(ECMO)의 도입이 진행되어 중증 환자의 생존율 향상에 기여하고 있습니다. 또한, 염증을 줄이고 폐 기능을 개선하기 위한 생물학적 제제 및 표적 치료제의 혁신도 시장에 긍정적인 영향을 미치고 있습니다. 임상 연구가 계속 발전함에 따라 치료 접근법은 더욱 개인화되고 효과적이 되어가고 있습니다.

시장 촉진요인

호흡기질환의 유병률 증가는 급성 폐 손상 치료 시장을 이끄는 주요 요인입니다. 폐렴, 패혈증으로 인한 폐 손상, 외상 관련 합병증과 같은 질병은 전 세계적으로 증가하고 있으며, 첨단 치료 솔루션에 대한 수요가 증가하고 있습니다. 대기오염, 흡연 등의 환경적 요인은 폐 건강 문제를 더욱 악화시키고 있습니다. 노년층은 특히 호흡기질환에 걸리기 쉽기 때문에 시장 성장에 크게 기여하고 있습니다. 또한, 중환자실 입원 환자 수가 증가함에 따라 인공호흡기 및 산소 공급 시스템의 사용도 증가하고 있습니다. 치료 효과 향상과 부작용 최소화에 초점을 맞춘 지속적인 연구개발 활동도 시장 확대를 가속화하고 있습니다.

비즈니스 기회

이 시장은 제약회사와 바이오테크놀러지 기업에게 큰 성장 기회를 제공하고 있습니다. 항염증제, 생물학적 제제, 재생의료 등 혁신적인 의약품 개발이 치료의 새로운 패러다임을 제시할 것으로 기대되고 있습니다. 줄기세포를 이용한 치료법이나 정밀의료에 투자하는 기업은 경쟁 우위를 확보할 가능성이 높습니다. 또한, 첨단 호흡 보조 기기에 대한 수요 증가는 의료기기 제조업체에게 기회로 작용하고 있습니다. 신흥 경제국, 특히 아시아태평양과 라틴아메리카에서는 의료 인프라 개선과 의료 투자 증가로 인해 새로운 성장의 길이 열리고 있습니다. 전략적 파트너십과 제휴가 혁신을 촉진하고 시장 범위를 확대할 것으로 예상됩니다.

지역별 분석

북미는 높은 의료 인프라, 높은 의료비 지출, 주요 산업 플레이어의 강력한 입지를 바탕으로 급성 폐손상 치료 시장에서 지배적인 위치를 차지하고 있습니다. 이 지역은 또한 광범위한 연구 개발 활동과 유리한 상환 정책의 혜택을 누리고 있습니다. 유럽은 호흡기질환에 대한 인식 제고와 정부의 집중 치료 서비스 강화 노력에 힘입어 북미에 이어 견조한 성장세를 보이고 있습니다. 아시아태평양은 환자 수 증가, 호흡기질환 발생률 증가, 의료 시설 접근성 확대로 인해 예측 기간 동안 가장 빠른 성장을 보일 것으로 예상됩니다. 라틴아메리카와 중동 및 아프리카는 의료 시스템에 대한 지속적인 투자와 첨단 치료 기술 도입 확대에 힘입어 점차 중요한 시장으로 부상하고 있습니다.

주요 기업

  • GlaxoSmithKline plc
  • Bayer AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Company
  • Octapharma AG
  • Ono Pharmaceutical Co., Ltd.
  • Asklepion Pharmaceuticals, LLC
  • Edesa Biotech
  • Direct Biologics
  • Windtree Therapeutics, Inc.
  • Apeiron Biologics AG
  • ReAlta Life Sciences, Inc.
  • Stemedica Cell Technologies, Inc.
  • Histocell

세분화

치료법별

  • 약물요법
  • 산소요법
  • 인공호흡
  • 체외막산소화장치(ECMO)

약품 등급별

  • 코르티코스테로이드
  • 항생제
  • 기관지확장제
  • 이뇨제
  • 혈관 확장제
  • 기타

적응증별

  • 급성 호흡곤란 증후군(ARDS)
  • 폐렴에 의한 폐 손상
  • 패혈증에 의한 폐 손상
  • 외상에 따른 폐 손상
  • 기타

투여 경로별

  • 정맥 내
  • 경구
  • 흡입

유통 채널별

  • 병원 약국
  • 소매 약국
  • 온라인 약국

지역별

  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카

목차

제1장 주요 요약

제2장 시장 개요

제3장 세계의 급성 폐손상 치료 시장 전망, 2020-2033년

제4장 북미의 급성 폐손상 치료 시장 전망, 2020-2033년

제5장 유럽의 급성 폐손상 치료 시장 전망, 2020-2033년

제6장 아시아태평양의 급성 폐손상 치료 시장 전망, 2020-2033년

제7장 라틴아메리카의 급성 폐손상 치료 시장 전망, 2020-2033년

제8장 중동 및 아프리카의 급성 폐손상 치료 시장 전망, 2020-2033년

제9장 경쟁 구도

제10장 부록

KSM

The Acute Lung Injury Treatment Market is steadily evolving as global healthcare systems intensify efforts to address severe respiratory conditions. Acute lung injury (ALI), including acute respiratory distress syndrome (ARDS), continues to present a critical burden due to its complex pathology and high fatality rates. The increasing incidence of respiratory infections, sepsis, trauma, and environmental risk factors has amplified the need for effective therapeutic interventions. Healthcare providers are increasingly focusing on early diagnosis and advanced treatment strategies to improve survival rates and patient outcomes. Continuous advancements in critical care medicine, combined with rising awareness about respiratory health, are contributing to the expansion of this market across developed and developing regions.

Market Insights

The Acute Lung Injury Treatment Market is projected to expand from 3.1 billion in 2026 to 3.9 billion by 2033, reflecting a compound annual growth rate (CAGR) of 3.30% over the forecast period. This growth is supported by increasing demand for intensive care treatments and supportive respiratory therapies. Pharmacological interventions, along with mechanical ventilation and oxygen therapy, remain key components of treatment protocols. Additionally, the adoption of extracorporeal membrane oxygenation (ECMO) is gaining traction in severe cases, enhancing survival rates in critical conditions. The market is also benefiting from innovations in biologics and targeted therapies that aim to reduce inflammation and improve lung function. As clinical research continues to evolve, treatment approaches are becoming more personalized and effective.

Market Drivers

The rising prevalence of respiratory diseases is a major factor driving the Acute Lung Injury Treatment Market. Conditions such as pneumonia, sepsis-induced lung injury, and trauma-related complications are increasing globally, leading to higher demand for advanced treatment solutions. Environmental factors such as air pollution and smoking further exacerbate lung health issues. The aging population is particularly vulnerable to respiratory disorders, contributing significantly to market growth. Additionally, the growing number of hospital admissions in intensive care units has increased the use of ventilators and oxygen support systems. Ongoing research and development activities focused on improving therapeutic outcomes and minimizing adverse effects are also accelerating market expansion.

Business Opportunity

The market offers considerable growth opportunities for pharmaceutical and biotechnology companies. The development of innovative drugs, including anti-inflammatory agents, biologics, and regenerative therapies, is expected to reshape the treatment landscape. Companies investing in stem cell-based therapies and precision medicine approaches are likely to gain a competitive advantage. Furthermore, the increasing demand for advanced respiratory support devices presents opportunities for medical device manufacturers. Emerging economies, particularly in Asia Pacific and Latin America, are creating new avenues for growth due to improving healthcare infrastructure and rising healthcare investments. Strategic partnerships and collaborations are anticipated to drive innovation and expand market reach.

Region Analysis

North America holds a dominant position in the Acute Lung Injury Treatment Market, supported by advanced healthcare infrastructure, high healthcare expenditure, and a strong presence of leading industry players. The region also benefits from extensive research and development activities and favorable reimbursement policies. Europe follows closely, driven by increasing awareness of respiratory diseases and government initiatives to enhance critical care services. The Asia Pacific region is expected to witness the fastest growth during the forecast period due to a large patient population, rising incidence of respiratory conditions, and expanding access to healthcare facilities. Latin America and the Middle East & Africa are gradually emerging as important markets, supported by ongoing investments in healthcare systems and increasing adoption of advanced treatment technologies.

Key Players

  • GlaxoSmithKline plc
  • Bayer AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Company
  • Octapharma AG
  • Ono Pharmaceutical Co., Ltd.
  • Asklepion Pharmaceuticals, LLC
  • Edesa Biotech
  • Direct Biologics
  • Windtree Therapeutics, Inc.
  • Apeiron Biologics AG
  • ReAlta Life Sciences, Inc.
  • Stemedica Cell Technologies, Inc.
  • Histocell

Segmentation

By Treatment Type

  • Pharmacological Therapy
  • Oxygen Therapy
  • Mechanical Ventilation
  • Extracorporeal Membrane Oxygenation (ECMO)

By Drug Class

  • Corticosteroids
  • Antibiotics
  • Bronchodilators
  • Diuretics
  • Vasodilators
  • Others

By Indication

  • Acute Respiratory Distress Syndrome (ARDS)
  • Pneumonia-induced Lung Injury
  • Sepsis-induced Lung Injury
  • Trauma-related Lung Injury
  • Others

By Route of Administration

  • Intravenous
  • Oral
  • Inhalation

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Acute Lung Injury Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Acute Lung Injury Treatment Market Outlook, 2020 - 2033

  • 3.1. Global Acute Lung Injury Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
    • 3.1.1. Pharmacological Therapy
    • 3.1.2. Oxygen Therapy
    • 3.1.3. Mechanical Ventilation
    • 3.1.4. Extracorporeal Membrane Oxygenation (ECMO)
  • 3.2. Global Acute Lung Injury Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 3.2.1. Corticosteroids
    • 3.2.2. Antibiotics
    • 3.2.3. Bronchodilators
    • 3.2.4. Diuretics
    • 3.2.5. Vasodilators
    • 3.2.6. Others
  • 3.3. Global Acute Lung Injury Treatment Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 3.3.1. Acute Respiratory Distress Syndrome (ARDS)
    • 3.3.2. Pneumonia-induced Lung Injury
    • 3.3.3. Sepsis-induced Lung Injury
    • 3.3.4. Trauma-related Lung Injury
    • 3.3.5. Others
  • 3.4. Global Acute Lung Injury Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 3.4.1. Intravenous
    • 3.4.2. Oral
    • 3.4.3. Inhalation
  • 3.5. Global Acute Lung Injury Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 3.5.1. Hospital Pharmacies
    • 3.5.2. Retail Pharmacies
    • 3.5.3. Online Pharmacies
  • 3.6. Global Acute Lung Injury Treatment Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.6.1. North America
    • 3.6.2. Europe
    • 3.6.3. Asia Pacific
    • 3.6.4. Latin America
    • 3.6.5. Middle East & Africa

4. North America Acute Lung Injury Treatment Market Outlook, 2020 - 2033

  • 4.1. North America Acute Lung Injury Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
    • 4.1.1. Pharmacological Therapy
    • 4.1.2. Oxygen Therapy
    • 4.1.3. Mechanical Ventilation
    • 4.1.4. Extracorporeal Membrane Oxygenation (ECMO)
  • 4.2. North America Acute Lung Injury Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 4.2.1. Corticosteroids
    • 4.2.2. Antibiotics
    • 4.2.3. Bronchodilators
    • 4.2.4. Diuretics
    • 4.2.5. Vasodilators
    • 4.2.6. Others
  • 4.3. North America Acute Lung Injury Treatment Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 4.3.1. Acute Respiratory Distress Syndrome (ARDS)
    • 4.3.2. Pneumonia-induced Lung Injury
    • 4.3.3. Sepsis-induced Lung Injury
    • 4.3.4. Trauma-related Lung Injury
    • 4.3.5. Others
  • 4.4. North America Acute Lung Injury Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 4.4.1. Intravenous
    • 4.4.2. Oral
    • 4.4.3. Inhalation
  • 4.5. North America Acute Lung Injury Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 4.5.1. Hospital Pharmacies
    • 4.5.2. Retail Pharmacies
    • 4.5.3. Online Pharmacies
  • 4.6. North America Acute Lung Injury Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.6.1. U.S. Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 4.6.2. U.S. Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 4.6.3. U.S. Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 4.6.4. U.S. Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 4.6.5. U.S. Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 4.6.6. Canada Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 4.6.7. Canada Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 4.6.8. Canada Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 4.6.9. Canada Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 4.6.10. Canada Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
  • 4.7. BPS Analysis/Market Attractiveness Analysis

5. Europe Acute Lung Injury Treatment Market Outlook, 2020 - 2033

  • 5.1. Europe Acute Lung Injury Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
    • 5.1.1. Pharmacological Therapy
    • 5.1.2. Oxygen Therapy
    • 5.1.3. Mechanical Ventilation
    • 5.1.4. Extracorporeal Membrane Oxygenation (ECMO)
  • 5.2. Europe Acute Lung Injury Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 5.2.1. Corticosteroids
    • 5.2.2. Antibiotics
    • 5.2.3. Bronchodilators
    • 5.2.4. Diuretics
    • 5.2.5. Vasodilators
    • 5.2.6. Others
  • 5.3. Europe Acute Lung Injury Treatment Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 5.3.1. Acute Respiratory Distress Syndrome (ARDS)
    • 5.3.2. Pneumonia-induced Lung Injury
    • 5.3.3. Sepsis-induced Lung Injury
    • 5.3.4. Trauma-related Lung Injury
    • 5.3.5. Others
  • 5.4. Europe Acute Lung Injury Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 5.4.1. Intravenous
    • 5.4.2. Oral
    • 5.4.3. Inhalation
  • 5.5. Europe Acute Lung Injury Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Retail Pharmacies
    • 5.5.3. Online Pharmacies
  • 5.6. Europe Acute Lung Injury Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.6.1. Germany Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 5.6.2. Germany Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 5.6.3. Germany Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 5.6.4. Germany Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 5.6.5. Germany Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.6. Italy Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 5.6.7. Italy Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 5.6.8. Italy Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 5.6.9. Italy Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 5.6.10. Italy Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.11. France Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 5.6.12. France Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 5.6.13. France Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 5.6.14. France Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 5.6.15. France Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.16. U.K. Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 5.6.17. U.K. Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 5.6.18. U.K. Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 5.6.19. U.K. Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 5.6.20. U.K. Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.21. Spain Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 5.6.22. Spain Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 5.6.23. Spain Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 5.6.24. Spain Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 5.6.25. Spain Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.26. Russia Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 5.6.27. Russia Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 5.6.28. Russia Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 5.6.29. Russia Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 5.6.30. Russia Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.31. Rest of Europe Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 5.6.32. Rest of Europe Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 5.6.33. Rest of Europe Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 5.6.34. Rest of Europe Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 5.6.35. Rest of Europe Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
  • 5.7. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Acute Lung Injury Treatment Market Outlook, 2020 - 2033

  • 6.1. Asia Pacific Acute Lung Injury Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
    • 6.1.1. Pharmacological Therapy
    • 6.1.2. Oxygen Therapy
    • 6.1.3. Mechanical Ventilation
    • 6.1.4. Extracorporeal Membrane Oxygenation (ECMO)
  • 6.2. Asia Pacific Acute Lung Injury Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 6.2.1. Corticosteroids
    • 6.2.2. Antibiotics
    • 6.2.3. Bronchodilators
    • 6.2.4. Diuretics
    • 6.2.5. Vasodilators
    • 6.2.6. Others
  • 6.3. Asia Pacific Acute Lung Injury Treatment Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 6.3.1. Acute Respiratory Distress Syndrome (ARDS)
    • 6.3.2. Pneumonia-induced Lung Injury
    • 6.3.3. Sepsis-induced Lung Injury
    • 6.3.4. Trauma-related Lung Injury
    • 6.3.5. Others
  • 6.4. Asia Pacific Acute Lung Injury Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 6.4.1. Intravenous
    • 6.4.2. Oral
    • 6.4.3. Inhalation
  • 6.5. Asia Pacific Acute Lung Injury Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Retail Pharmacies
    • 6.5.3. Online Pharmacies
  • 6.6. Asia Pacific Acute Lung Injury Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.6.1. China Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 6.6.2. China Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 6.6.3. China Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 6.6.4. China Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 6.6.5. China Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.6. Japan Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 6.6.7. Japan Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 6.6.8. Japan Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 6.6.9. Japan Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 6.6.10. Japan Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.11. South Korea Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 6.6.12. South Korea Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 6.6.13. South Korea Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 6.6.14. South Korea Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 6.6.15. South Korea Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.16. India Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 6.6.17. India Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 6.6.18. India Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 6.6.19. India Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 6.6.20. India Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.21. Southeast Asia Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 6.6.22. Southeast Asia Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 6.6.23. Southeast Asia Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 6.6.24. Southeast Asia Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 6.6.25. Southeast Asia Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.26. Rest of SAO Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 6.6.27. Rest of SAO Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 6.6.28. Rest of SAO Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 6.6.29. Rest of SAO Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 6.6.30. Rest of SAO Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
  • 6.7. BPS Analysis/Market Attractiveness Analysis

7. Latin America Acute Lung Injury Treatment Market Outlook, 2020 - 2033

  • 7.1. Latin America Acute Lung Injury Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
    • 7.1.1. Pharmacological Therapy
    • 7.1.2. Oxygen Therapy
    • 7.1.3. Mechanical Ventilation
    • 7.1.4. Extracorporeal Membrane Oxygenation (ECMO)
  • 7.2. Latin America Acute Lung Injury Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 7.2.1. Corticosteroids
    • 7.2.2. Antibiotics
    • 7.2.3. Bronchodilators
    • 7.2.4. Diuretics
    • 7.2.5. Vasodilators
    • 7.2.6. Others
  • 7.3. Latin America Acute Lung Injury Treatment Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 7.3.1. Acute Respiratory Distress Syndrome (ARDS)
    • 7.3.2. Pneumonia-induced Lung Injury
    • 7.3.3. Sepsis-induced Lung Injury
    • 7.3.4. Trauma-related Lung Injury
    • 7.3.5. Others
  • 7.4. Latin America Acute Lung Injury Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 7.4.1. Intravenous
    • 7.4.2. Oral
    • 7.4.3. Inhalation
  • 7.5. Latin America Acute Lung Injury Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Retail Pharmacies
    • 7.5.3. Online Pharmacies
  • 7.6. Latin America Acute Lung Injury Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.6.1. Brazil Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 7.6.2. Brazil Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 7.6.3. Brazil Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 7.6.4. Brazil Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 7.6.5. Brazil Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 7.6.6. Mexico Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 7.6.7. Mexico Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 7.6.8. Mexico Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 7.6.9. Mexico Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 7.6.10. Mexico Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 7.6.11. Argentina Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 7.6.12. Argentina Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 7.6.13. Argentina Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 7.6.14. Argentina Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 7.6.15. Argentina Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 7.6.16. Rest of LATAM Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 7.6.17. Rest of LATAM Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 7.6.18. Rest of LATAM Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 7.6.19. Rest of LATAM Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 7.6.20. Rest of LATAM Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
  • 7.7. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Acute Lung Injury Treatment Market Outlook, 2020 - 2033

  • 8.1. Middle East & Africa Acute Lung Injury Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
    • 8.1.1. Pharmacological Therapy
    • 8.1.2. Oxygen Therapy
    • 8.1.3. Mechanical Ventilation
    • 8.1.4. Extracorporeal Membrane Oxygenation (ECMO)
  • 8.2. Middle East & Africa Acute Lung Injury Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 8.2.1. Corticosteroids
    • 8.2.2. Antibiotics
    • 8.2.3. Bronchodilators
    • 8.2.4. Diuretics
    • 8.2.5. Vasodilators
    • 8.2.6. Others
  • 8.3. Middle East & Africa Acute Lung Injury Treatment Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 8.3.1. Acute Respiratory Distress Syndrome (ARDS)
    • 8.3.2. Pneumonia-induced Lung Injury
    • 8.3.3. Sepsis-induced Lung Injury
    • 8.3.4. Trauma-related Lung Injury
    • 8.3.5. Others
  • 8.4. Middle East & Africa Acute Lung Injury Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 8.4.1. Intravenous
    • 8.4.2. Oral
    • 8.4.3. Inhalation
  • 8.5. Middle East & Africa Acute Lung Injury Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Retail Pharmacies
    • 8.5.3. Online Pharmacies
  • 8.6. Middle East & Africa Acute Lung Injury Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.6.1. GCC Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 8.6.2. GCC Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 8.6.3. GCC Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 8.6.4. GCC Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 8.6.5. GCC Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.6. South Africa Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 8.6.7. South Africa Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 8.6.8. South Africa Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 8.6.9. South Africa Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 8.6.10. South Africa Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.11. Egypt Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 8.6.12. Egypt Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 8.6.13. Egypt Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 8.6.14. Egypt Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 8.6.15. Egypt Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.16. Nigeria Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 8.6.17. Nigeria Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 8.6.18. Nigeria Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 8.6.19. Nigeria Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 8.6.20. Nigeria Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.21. Rest of Middle East Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 8.6.22. Rest of Middle East Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 8.6.23. Rest of Middle East Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 8.6.24. Rest of Middle East Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 8.6.25. Rest of Middle East Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
  • 8.7. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. GlaxoSmithKline plc
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Bayer AG
    • 9.4.3. Pfizer Inc.
    • 9.4.4. Teva Pharmaceutical Industries Ltd.
    • 9.4.5. Eli Lilly and Company
    • 9.4.6. Octapharma AG
    • 9.4.7. Ono Pharmaceutical Co., Ltd.
    • 9.4.8. Asklepion Pharmaceuticals, LLC
    • 9.4.9. Edesa Biotech
    • 9.4.10. Direct Biologics
    • 9.4.11. Windtree Therapeutics, Inc.
    • 9.4.12. Apeiron Biologics AG
    • 9.4.13. ReAlta Life Sciences, Inc.
    • 9.4.14. Stemedica Cell Technologies, Inc.
    • 9.4.15. Histocell

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
×

원하시는 정보를 찾아 드릴까요?

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
kr-info@giikorea.co.kr
문의하기